Cargando…
P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430512/ http://dx.doi.org/10.1097/01.HS9.0000972164.39454.e5 |
| _version_ | 1785090981790482432 |
|---|---|
| author | Cremer, Anjali Enssle, Julius C. Pfaff, Saskia Kouidri, Khouloud Lang, Fabian Brandts, Christian Zeiher, Andreas Cremer, Sebastian Steffen, Björn Serve, Hubert Bug, Gesine |
| author_facet | Cremer, Anjali Enssle, Julius C. Pfaff, Saskia Kouidri, Khouloud Lang, Fabian Brandts, Christian Zeiher, Andreas Cremer, Sebastian Steffen, Björn Serve, Hubert Bug, Gesine |
| author_sort | Cremer, Anjali |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430512 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104305122023-08-17 P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT Cremer, Anjali Enssle, Julius C. Pfaff, Saskia Kouidri, Khouloud Lang, Fabian Brandts, Christian Zeiher, Andreas Cremer, Sebastian Steffen, Björn Serve, Hubert Bug, Gesine Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430512/ http://dx.doi.org/10.1097/01.HS9.0000972164.39454.e5 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Cremer, Anjali Enssle, Julius C. Pfaff, Saskia Kouidri, Khouloud Lang, Fabian Brandts, Christian Zeiher, Andreas Cremer, Sebastian Steffen, Björn Serve, Hubert Bug, Gesine P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT |
| title | P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT |
| title_full | P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT |
| title_fullStr | P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT |
| title_full_unstemmed | P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT |
| title_short | P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT |
| title_sort | p1319: treatment with midostaurin and other flt3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients with flt3 mutated aml who underwent allogeneic hct |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430512/ http://dx.doi.org/10.1097/01.HS9.0000972164.39454.e5 |
| work_keys_str_mv | AT cremeranjali p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT ensslejuliusc p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT pfaffsaskia p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT kouidrikhouloud p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT langfabian p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT brandtschristian p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT zeiherandreas p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT cremersebastian p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT steffenbjorn p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT servehubert p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct AT buggesine p1319treatmentwithmidostaurinandotherflt3targetinginhibitorsisassociatedwithanincreasedriskofcardiovascularadverseeventsinpatientswithflt3mutatedamlwhounderwentallogeneichct |